presentation

Hafnias Q3 2025 Financial Results Presentation to Be Held on 1 December 2025

SINGAPORE--(BUSINESS WIRE)--Hafnia Limited (“Hafnia”, the “Company”, OSE ticker code: “HAFNI”, NYSE ticker code “HAFN”) will release its Q3 2025 results…

2 days ago

Netrack Showcases Innovative iRack Solutions at BICSI India Technology Seminar in Bengaluru

Netrack, a leader and a renowned name in innovation and manufacturing of data center and IT infrastructure solutions, recently participated…

3 weeks ago

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

October 24, 2025 07:00 ET  | Source: Sagimet Biosciences Inc. Denifanstat met all primary and secondary endpoints versus placebo and…

1 month ago

Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered…

1 month ago

The Shaw Prize Award Presentation Ceremony 2025: Continuing 22 Years of Legacy in Science and Innovation

HONG KONG, Oct. 21, 2025 /PRNewswire/ -- The Shaw Prize presented its awards to four 2025 Shaw Laureates today at…

1 month ago

Netrack Engages Industry Leaders at BICSI Chennai with Future-oriented IT-solutions

Netrack’s participation in the BICSI event in Chennai on December 21st 2024, marked the year with productivity and success. As…

1 month ago

Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platforms Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer

Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and remains an aggressive disease with median survival…

1 month ago

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led…

2 months ago

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer…

2 months ago

Patients Taking AUSTEDO XR (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR®…

2 months ago